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ORIGINAL ARTICLE
Long-term treatment with probiotics in primary care patients with
irritable bowel syndrome – a randomised, double-blind, placebo
controlled trial
LUISE MØLENBERG BEGTRUP1,2, OVE B SCHAFFALITZKY DE MUCKADELL2,
JENS KJELDSEN2, RENÉ DEPONT CHRISTENSEN1 & DORTE EJG JARBØL1
1Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense, Denmark, and
2Department of Medical Gastroenterology, Odense University Hospital, University of Southern Denmark, Odense,
Denmark
Abstract
Objective.Meta-analyses have indicated effect of probiotics on irritable bowel syndrome (IBS). However, few long-term trials
have been conducted and uncertainty remains as to effectiveness and long-term effect in a primary care setting. We aimed to
investigate the effect of probiotics compared with placebo in the management of IBS in primary care during a 6-month
treatment period and with a 6-month follow-up. Material and methods. We randomized IBS patients fulﬁlling Rome III
criteria to receive two capsules twice daily either containing placebo or a probiotic mixture of Lactobacillus paracasei ssp paracasei
F19, Lactobacillus acidophilus La5 and Biﬁdobacterium Bb12 in an amount of 1.3 1010 CFU per capsule. Primary endpoint was
proportion of responders deﬁned as patients reporting adequate relief (AR) at least 50% of the time in the 6-month treatment
period. Secondary outcomes were proportions of patients reporting AR at different time points, and change in gastrointestinal
symptoms and health-related quality of life (HrQOL) from baseline to 6 and 12 months. Results. A total of 131 patients were
included in this study. The proportion of responders in the treatment period was 52% (35/67) in the probiotic group versus
41% (26/64) in the placebo group, p = 0.18. Overall we found no difference between the groups in change in gastrointestinal
symptoms after treatment. Patients improved in HrQOL, but with no statistically signiﬁcant difference between the groups.
Conclusion.During a 6-month treatment period, we were not able to detect a positive effect of probiotic when compared with
placebo.
Key Words: irritable bowel syndrome, primary health care, probiotics, randomized controlled trial
Introduction
Irritable bowel syndrome (IBS) is characterized by
chronic or recurrent symptoms attributed to the gas-
trointestinal (GI) tract in the absence of an organic
explanation. IBS is very common affecting about 12%
in Western populations [1]. The exact pathophysio-
logical mechanisms are unknown, and many
physiological explanations have been raised, such as
abnormal GI motility, visceral hypersensitivity, altered
brain gut function, low-grade chronic inﬂammation
and alteration in intestinal ﬂora.
In recent years, an increasing focus has been on a
possible inﬂuence on the gut microbiota. The current
working hypothesis is that abnormal microbiota acti-
vate mucosal innate immune responses, thereby
increasing epithelial permeability and activating
nociceptive sensory pathways and dysregulating the
enteric nervous system [2]. Clinical evidence for this
is supported by the fact that: 1) IBS symptoms can
develop in predisposed individuals following an
enteric infection [3], 2) treatments targeting the
microbiota such as antibiotics [4], probiotics [5]
and prebiotics [6] have been suggested to be effective
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and 3) the fecal microbiota has proved to be signif-
icantly altered in IBS patients compared to healthy
controls [7,8].
Trials with probiotics have been conducted and
meta-analyses indicate effect on global symptoms
with number needed to treat (NNT) ranging from
4 to 21 [5,9,10]. Unfortunately, these trials have been
very heterogeneous using different probiotic strains,
doses and outcomes. Furthermore, many trials had
methodological limitations. Proofs of efﬁcacy have
often been based on reported change in composite
or speciﬁc symptoms scores not integrating clinical
relevance for the patient. Since IBS is a chronic and
relapsing condition and severity as well as symptoms
may vary in the same patient over time, long-
term efﬁcacy trials are needed. Unfortunately, only
few long-term trials have been conducted and none of
them with long follow-up [11–13]. Probiotics do not
colonize the GI tract, but may in theory create an
aberrant ﬂora giving the patient symptoms after ces-
sation of treatment. A long follow-up provides oppor-
tunity to determine treatment durability and potential
worsening of symptoms after cessation of treatment.
The aim of this study was to investigate the effect of
probiotics compared with placebo in the management
of IBS in a primary care population during a 6-month
treatment period and with a 6-month follow-up.
Methods
We conducted a randomized double-blind, placebo-
controlled trial with two parallel groups. Patients
were included from January 2009 to June 2010 and
followed for 1 year.
Participants and setting
The target group was patients aged 18–50 years,
consulting with GI complaints and suspected of
IBS by their general practitioner (GP). GPs referred
patients to the study, where they were assessed for
eligibility. Enrollment took place at the Research Unit
of General Practice in Odense, Denmark. Inclusion
criteria were informed written consent and fulﬁllment
of Rome III criteria. Exclusion criteria were a) pres-
ence of alarm signals (unexplained weight loss >3 kg
within the past 3 months, rectal bleeding, unexplained
fever, unexplained anaemia, family history of inﬂam-
matory bowel disease (IBD) or colorectal cancer
(CRC), abnormal physical examination), b) medicine
or alcohol abuse, c) pregnancy, d) severe comorbidity
interfering with evaluation of outcomes and e) dura-
tion of symptoms less than 1 year in patients aged
above 40. The last criterion was a consequence of the
Danish guidelines on CRC. All eligible patients were
ﬁrst allocated to a study concerning the diagnostic
process of IBS [14]. Patients were excluded if
receiving an organic diagnosis during the diagnostic
program. All patients with a ﬁnal diagnosis of IBS
were included in this study and randomly allocated to
capsules with probiotics or placebo. Two capsules
were to be taken twice daily for 6 months. After
3 and 6 months patients attended study visits with
a study nurse, where residual capsules were counted
and questions about symptoms and adverse effects
assessed. After completing the 6-month intervention
patients were followed for another 6 months and
attended a ﬁnal 12-month study visit. Every month
patients completed a questionnaire concerning
symptoms (adequate relief (AR) and GI symptoms).
Further questionnaires concerning HrQOL were
answered at baseline, 6 months and 12 months. Infor-
mation on demographics, previous symptoms and
previous use of resources was collected in a structured
interview at ﬁrst encounter.
The probiotic
The probiotic capsules contained Lactobacillus para-
casei ssp paracasei F19, Lactobacillus acidophilus
La5 and Biﬁdobacterium Bb12 in doses of 3  109
to 7  109 yielding a total content of all strains of
1.3  1010 CFU per capsule. To achieve the same
dose as in former trials conducted with the same
probiotic mixture [15,16], 4 capsules were to be
consumed. The probiotic capsules were provided
by the Danish-Swedish cooperative dairy company
Arla Foods. The placebo capsules contained, like the
active capsules, maltodextrin. Patients were advised
against taking any other kind of probiotic during the
study period but consumption of lactic acid bacteria
in ordinary sour milk products was permitted.
Endpoints/questionnaires
Primary endpoint was proportions of patients report-
ing AR of their IBS symptoms at least 50% of the time
during the 6-month treatment period. Once a month
patients had to answer the question: “in the past seven
days have you had adequate relief of your irritable bowel
syndrome pain or discomfort?(yes/no) The question was
translated into Danish by an independent bilingual
secretary. Secondary endpoints were change in GI
symptoms from baseline to 3, 6 and 12 months,
measured by the Gastrointestinal Symptom Rating
Scale modiﬁed for use in patients with IBS (GSRS-
IBS) [17], and change in health-related quality of life
from baseline till after 6 and 12 months measured by
Irritable Bowel Syndrome Quality of Life measure-
ment (IBS-QOL) [18,19]. We further assessed
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proportion of patients reporting AR at each time point
(every month) during 12 months.
Compliance
Patients were considered compliant, if they ingested
at least 80% of the planned capsules. We counted the
number of capsules remaining in each returned box in
order to determine the degree of compliance.
Compliance was veriﬁed by an subanalysis of a
random sample of fecal samples (after 3 months of
treatment), investigating the presence of Lactobacillus
paracasei ssp paracasei F19 (F19), Lactobacillus aci-
dophilus La5 (LA-5) and Biﬁdobacterium Bb12
(BB-12). A total of 52 samples were analyzed, of
which 29 samples were from patients who had
received probiotics. Colonies were isolated on speciﬁc
substrates. The presence of the probiotic strain was
then conﬁrmed by counting all the characteristic
colonies on the different substrates, by microscopy
and by a qualitative analysis using RAPD-PCR [20].
Randomisation and masking
To ensure balance between the groups during the trial
the patients were randomized into blocks of four. The
size of the block was unknown to the investigator.
Concealed allocation was ensured by the distribution
of investigational products through an organization
within Arla Foods, otherwise not involved in this
study. The capsules appeared completely identical
and were packed in identical boxes labeled with
participant number based on a randomization list.
The randomization list was kept at Arla Foods during
the entire study phase. The investigator handed out
boxes consecutively and registered the participant
number for each patient. The blinding was main-
tained until the data analysis was completed.
The study was approved by the local ethics com-
mittee in the Region of Southern Denmark (Project
no. S-20080078, 07.17.2008). Informed consent was
obtained from all patients. The trial was registered in
Clinical trials: NCT01151657
Statistics
We wanted, in line with Simrén [15], to detect a 30%
therapeutic beneﬁt in proportions of responders after
6 months of treatment and with 80% power at
a = 0.05, using a two-sided test and assuming a
15% placebo response. At least 70 persons should
be included, but as we suspected dropouts, given the
long treatment period and follow-up, we included all
patients eligible, thus resulting in 131 patients.
The primary endpoint was analyzed based on the
intention to treat (ITT) principle with drop outs
counting as non-responders and missing values
regarded as not having AR. A subgroup analysis
excluding patients not being bothered by symptoms
(= reporting AR) at baseline was performed. We
further analyzed the primary endpoint based on the
per-protocol population and excluding patients not
being bothered by symptoms at baseline.
Change in GI symptoms was analyzed for the
population of patients having answered the baseline
monthly letter and the 3-, 6- and 12-monthly letter,
respectively. Change in HrQOL was analyzed for the
population having answered the baseline question-
naire and the 6- and 12-month questionnaire, respec-
tively. Proportions of patients having AR at every time
point (month) were analyzed as ITT with missing
values regarded as not having AR.
Normally distributed continuous measures are
reported as mean and SD, and group comparisons
were performed using Student’s t-tests. Categorical
data are reported as absolute number and percentage
and compared using Chi-squared tests. All tests were
two-sided and for the primary endpoint statistical
signiﬁcance was accepted at the 5% level.
Regarding the secondary endpoints no formal
adjustment for multiplicity was performed.
Due to a high drop-out rate, we performed sensi-
tivity analyses, regarding change in GI symptoms and
change in HrQOL, taking the baseline values into
account.
Results
A total of 306 patients were referred for the study, of
these 244 patients were assessed for eligibility,
leaving153 patients investigated and 131 patients
included and randomly allocated to probiotics or
placebo. A total of 67 patients were assigned to
probiotic capsules and 64 patients to placebo: of these
54 patients (81%) and 46 patients (72%) completed
the intervention, respectively. Dropouts were younger
and had a shorter history of symptoms. Reasons for
dropout are shown in Figure 1. Of the 100 patients
completing the intervention, 55 patients were fully
compliant during all 6 months. Some 97 (74%) of the
included patients were women.Mean age was 31 years
and mean duration of symptoms 6.8 years. It was
equally distributed in the two groups (Table I).
Among the patients completing the intervention
2% of the monthly letters were missing in the 6-month
treatment period.
Primary outcome
After 6 months of treatment the number of responders
were 35 (52%) in the probiotic group versus 26 (41%)
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in the placebo group, yielding an absolute risk differ-
ence of 11%, 95% CI-interval (–5, 29), p = 0.18. In
the subgroup analysis excluding patients not being
bothered by symptoms (= reporting AR) at baseline
(n = 79) the number of responders was 15 (39%) in
the probiotic group versus 12 (29%) in the placebo
group, p = 0.34. In the per-protocol analysis excluding
patients not being bothered by symptoms (= reporting
Analysed
ITT (n = 64)
Per protocol, treatment, n = 23
♦  Not included in the per protocol analysis, n = 41
-  Drop outs (n = 18)
-  Compliance not sufficient (n = 16)
-  Not answered all questions during treatment (n = 7)
Per protocol, treatment & follow-up n = 19
♦  Not included in the per protocol analysis, n = 45
-  Drop outs (n = 23)
-  Compliance not sufficient (n = 16)
-  Not answered all questions during treatment (n = 6*) 
*1 patient dropped out during follow-up, and did not answer all questions
during treatment 
Assessed for eligibility, n = 244
Excluded, n = 91
•  Did not fulfill the Rome III criteria (n = 55)
•  Fulfilled exclusion criteria (n = 36)
Analysed
ITT (n = 67) 
Per protocol, treatment, n = 24
♦  Not included in the per protocol analysis, n = 43
-  Drop outs (n = 13)
-  Compliance not sufficient (n = 29)
-  Not answered all questions during treatment (n = 1)
Per protocol, treatment & follow-up, n = 23 
♦  Not included in the per protocol analysis, n = 44
-  Drop outs (n = 14)
-  Compliance not sufficient (n = 29)
-  Not answered all questions during treatment (n = 1) 
Completed the intervention (6 months), n = 54 
♦  Did not complete the intervention, n = 13
 -  Lack of time and energy (n = 10)
-  No effect of the capsules (n = 1)
-  Pregnancy (n = 1)
-  Side effects (n = 1)  
Allocated to probiotics 
♦  Received allocated intervention, n = 67
♦  Did not receive allocated intervention, n = 0
Completed the intervention (6 months), n = 46 
♦  Did not complete the intervention, n = 18
-  Lack of time and energy (n = 10)
-  Pregnancy (n = 2)
-  No effect of the capsules (n = 3)
-  Other reason (n = 3)
Allocated to placebo 
♦  Received allocated intervention, n = 64
♦  Did not receive allocated intervention, n = 0
Allocation
Follow-up
Patients fulfilling Rome III, having no alarm signals, n = 153
Enrollment
Referred patients, n = 306
Completed the follow up (12 months), n = 53
♦  Did not complete the follow up, n = 1
  -  Not attending visit 4 (n = 1) 
Completed the follow up (12 months), n = 41 
♦  Did not complete the follow up, n = 5
-  Not attending visit 4 (n = 1)
-  Lack of time and energy (n = 1)
-  Pregnancy (n = 3)
Analysis
Excluded, n = 62
•  > 50 years of age (n = 11)
•  < 18 years of age (n = 1)
•  Not appearing at visit 1 (n = 26)
•  Declined to participate (n = 24)
Patients randomized, n = 131
Excluded, n = 22
•  Other diagnosis than IBS (n = 10)
•  Withdrawn consent (n = 8)
•  Travelled abroad and was not able to
     receive capsules (n = 1)
•  Other reason (n = 3) 
Figure 1. Flow chart demonstrating the number of patients in the different phases of the trial.
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AR) at baseline (n = 23) the numbers were 7 (47%)
versus 2 (25%), p = 0.31.
Secondary outcomes
After 3 months of treatment, we observed a difference
between the groups regarding total score as well as
diarrhea, satiety and bloating. However, after
6 months of treatment no differences were observed.
After the additional 6 months of follow-up a differ-
ence in total score, pain and satiety was observed. All
the observed differences were in favour of the placebo
group (Table II).
Patients improved in HrQOL during the trial, but
with no difference between the groups (Table III).
The sensitivity analyses taking into account the
baseline values did not change the estimates.
Reported AR at each time point (months) in the
two groups is shown in Figure 2. The proportion of
patients having AR was ﬂuctuating but declined dur-
ing follow-up in both groups. In the probiotic group
the proportion of patients having AR was most pro-
nounced at 3 and 6 months, while in the placebo
group the greatest effect was seen after 1 month of
treatment. We observed no worsening in symptoms in
the probiotic group after cessation of treatment when
compared with placebo.
Compliance
Of the patients completing the treatment 55 patients
were compliant as deﬁned in the study protocol,
25 patients (46%) in the probiotic group and
Table I. Baseline characteristics of the randomised patients.
Total
n = 131
Probiotics
n = 67
Placebo
n = 64
Demographic
Gender, female n (%) 97 (74) 51 (76) 46 (72)
Age, mean (SD) 30.52 (9.42) 31.63 (10.05) 29.38 (8.64)
Race, Danish origin n (%) 125 (95) 63 (94) 62(97)
Health related
Bodymass index, mean (SD) 24.56 (4.15) 24.68 (4.60) 24.42(3.64)
Allergy, n (%) 43 (33) 20 (30) 23 (36)
Smoking, yes n (%) 31 (24) 18 (27) 13 (20)
Symptoms
Duration of symptoms, years, mean (SD) 6.82 (6.99) 7.13 (6.95) 6.50 (7.03)
Severity last 7 days, n (%)
No symptoms 2(2) 1 (1) 1 (2)
Mild 42(32) 22 (33) 20 (31)
Moderate 80(61) 39 (58) 41 (64)
Severe 7(5) 5 (7) 2 (3)
First episode associated with acute diarrhea, n (%) 18 (14) 10 (15) 8 (13)
GSRS-IBS, 1–7
Total score, mean (SD) 3.09 (0.93) 3.05 (0.96) 3.13 (0.89)
IBS-subtype, n (%)
IBS with constipation, IBS-C 25 (19) 14 (21) 11 (17)
IBS with diarrhea, IBS-D 53 (40) 25 (37) 28 (44)
IBS mixed, IBS-M 50 (38) 25 (37) 25 (39)
IBS undeﬁned, IBS-D 3 (2) 3 (4) -
Prior treatment
Previous use of medicine, n (%) 97(74) 52(78) 45 (70)
Previous use of:
Ispaghula, n (%) 61(47) 31(46) 30(47)
Antispasmodics, n (%) 11 (9) 4(7) 7(12)
Laxatives, n (%) 21(17) 8(13) 13(22)
Loperamide, n (%) 11 (9) 8 (13) 3 (5)
Use of Complementary medicine, n (%) 47 (37) 25 (38) 22 (35)
Health-related quality of life
SF-36
PCS, mean, (SD) 49.00 (7.51) 48.27(7.38) 49.63 (7.60)
MCS, mean (SD) 48.26 (10.44) 49.10(9.99) 47.43(10.90)
IBS-QOL, total score (SD) 73.33 (17.83) 73.23 (17.21) 73.43 (18.61)
Psychological co morbidity
HADS
Anxiety score 7.10 (3.75) 6.81 (3.43) 7.42 (4.07)
Depression score 3.92 (3.5) 3.64 (3.29) 4.21 (3.71)
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30 patients (65%) in the placebo group respectively.
There was no difference between compliant and non-
compliant patients concerning age, sex and IBS sub-
types. In the probiotic group 18 (62%) of the non-
compliant patients were, however, compliant in 3 of
the 6 treatment months.
We found probiotic strains in 23 (79%) samples
from the probiotic group (LA-5 in 3(10%), BB-12 in
20(74%), and F19 in 11(39%)). None of the three
probiotic strains were found in the feces of the sub-
jects in the placebo group.
Adverse effects
No serious adverse affects were reported. In the
probiotic group one patient reported an itching rash
on forearms and thighs and dropped out and another
patient reported a transient rash at elbows and thumbs
but continued treatment.
Discussion
In this long-term treatment trial in a primary care
population, we were not able to show that the
probiotic mixture containing Lactobacillus paracasei
ssp paracasei F19, Lactobacillus acidophilus La5 and
Biﬁdobacterium Bb12 had superior efﬁcacy compared
to placebo. Although the group treated with probio-
tics had a greater proportion of responders, this was
not statistically signiﬁcant. The effect of treatment
was ﬂuctuating in both groups. After treatment it
declined.
The study was a 6-month, randomized, double-
blind, placebo-controlled trial which is the optimal
design when investigating efﬁcacy of treatments. The
length of the study provided the opportunity to inves-
tigate whether long-term treatment is feasible in IBS,
a disorder characterized by chronic and intermittent
symptoms. Further this is the ﬁrst study with a long
follow-up providing the possibility of examining
durability of treatment.
A major strength of the study is the recruitment of
patients from primary care, since most IBS patients
are managed here. All included patients fulﬁlled the
Rome III criteria. The criteria have demonstrated a
good sensitivity relative to a clinical diagnosis of IBS
made by GPs in primary care [21], and we believe that
Table II. Change in gastrointestinal symptoms from baseline, GSRS-IBSa.
Baseline After 3 months treatment After 6 months treatment After 6 months followup
Probiotic
n = 67
Placebo
n = 64
Probiotic
n = 54
Placebo
n = 48 p*
Probiotic
n = 54
Placebo
n = 44 p**
Probiotic
n = 48
Placebo
n = 38 p***
Total score, mean (SD) 3.0 (1.0) 3.1 (0.9) 3.0 (1.2) 2.6 (0.8) 0.008 2.9 (1.1) 2.8 (1.0) 0.460 2.9 (1.1) 2.8 (0.9) 0.021
Pain, mean (SD) 3.3 (1.2) 3.5(1.2) 3.2(1.3) 3.0(1.1) 0.163 3.1 (1.3) 3.1(1.3) 0.799 3.2 (1.2) 2.9 (1.0) 0.035
Constipation, mean (SD) 2.4 (1.3) 2.6 (1.4) 2.4 (1.4) 2.3 (1.2) 0.348 2.3 (1.6) 2.3 (1.3) 0.652 2.4 (1.5) 2.2 (1.3) 0.147
Diarrhea, mean (SD 2.9 (1.3) 3.0 (1.2) 2.9 (1.4) 2.5 (1.1) 0.040 2.8 (1.4) 2.8 (1.3) 0.862 2.7 (1.2) 2.7 (1.2) 0.214
Satiety, mean (SD) 2.6 (1.4) 2.4 (1.4) 2.8 (1.6) 1.9 (1.2) 0.007 2.6 (1.4) 2.2 (1.3) 0.171 2.6 (1.3) 2.0 (1.4) 0.017
Bloating, mean (SD) 3.8 (1.3) 4.0 (1.4)) 3.7 (1.6) 3.3 (1.3) 0.048 3.7 (1.4) 3.5 (1.3) 0.340 3.7 (1.5) 3.5 (1.1) 0.159
aGastrointestinal Symptom Rating Scale speciﬁc for IBS/GSRS-IBS. Range 1–7. Increasing values reﬂect increasing symptoms.
*Difference between the groups concerning change in gastrointestinal symptoms from baseline till after 3 months treatment.
**Difference between the groups concerning change in gastrointestinal symptoms from baseline till after 6 months treatment.
***Difference between the groups concerning change in gastrointestinal symptoms from baseline till after 6 months follow-up.
Table III. Change in health-related quality of life from baseline, IBS-QOLa.
Baseline After 6 months treatment After 6 months followup
Probiotic
n = 62
Placebo
n = 59
Probiotic
n = 59
Placebo
n = 49 p-Value*
Probiotic
n = 59
Placebo
n = 51 p-Value**
Total score, mean (SD) 73.2 (17.2) 73.4 (18.6) 78.3 (15.6) 78.0 (16.4) 0.535 81.7 (11.3) 77.1(16.7) 0.497
Dysphoria, mean (SD) 78.6 (20.5) 76.5 (23.0) 84.3 (17.1) 82.3 (19.9) 0.630 88.5 (12.2) 82.4 (20.1) 0.790
Interference, mean (SD) 69.6 (18.8) 73.2 (20.8) 77.1 (17.6) 77.1 (20.9) 0.377 80.5 (13.8) 74.3 (20.5) 0.310
Body image, mean (SD) 64.5 (21.3) 66.1 (23.1) 71.0 (21.2) 73.1 (19.3) 0.207 73.4 (15.1) 70.3 (19.7) 0.173
Health worry, mean (SD) 79.0 (19.0) 78.0 (17.4) 79.9 (15.4) 80.3 (15.3) 0.212 83.3 (11.7) 80.8 (15.7) 0.214
Food avoidance, mean (SD) 56.9 (29.7) 64.8 (26.8) 61.6 (26.3) 68.1 (24.9) 0.762 67.0 (20.6) 66.0 (26.5) 0.561
Social reaction, mean (SD) 73.7 (20.8) 73.8 (21.9) 80.5 (19.4) 77.0 (19.5) 0.371 82.8 (18.4) 75.8 (21.5) 0.561
Sexual, mean (SD) 78.2 (26.1) 72.5 (32.1) 82.4 (22.7) 79.6 (25.7) 0.580 86.7 (16.8) 80.6 (20.5) 0.962
Relations, mean (SD) 81.6 (20.3) 80.4 (20.2) 84.2 (19.8) 83.5 (16.7) 0.911 88.6 (15.3) 83.6 (17.3) 0.698
aDisease speciﬁc HRQOL-questionaire, IBS-QOL. Range 0–100. Increasing values reﬂect increased well-being.
*Difference between the groups concerning change from baseline till 6 months.
**Difference between the groups concerning change from baseline till 12 months.
1132 L. M. Begtrup et al.
our population represents IBS patients in primary
care well.
We used the subjective global assessment AR, as we
believe it is a clinically relevant outcome including
symptom burden and using the patients own refer-
ence system. Furthermore, AR is validated [22] and
recommended for use in IBS trials [23,24].
Certain limitations of the study should be acknowl-
edged. Due to the length of the study it was reason-
able to include patients with intermittent symptoms
and we chose to include all patients in the analysis
irrespective of baseline AR status. Based on a large
patient-level meta-analysis a Rome Foundation report
has concluded that AR is not impacted by baseline
severity [22]. However, effect of baseline severity on
ARs validity is much debated [25,26]. The subgroup
analysis of the primary outcome including only
patients not having AR at baseline revealed a lower
overall number of responders, but almost the same
difference in proportions of responders between the
groups.
The study was a long-term trial with a duration
exceeding that of most studies conducted [5]. To
make it feasible we decided, that the patients should
answer the AR question once monthly. Whether this
is acceptable could be questioned. However, we
believe that the responder deﬁnition of having AR
50% of the time during treatment covers a long time
span, ensuring a true picture of the patients contin-
uous symptoms. The monthly interval between mea-
surements is comparable with the design in the two
former trials lasting 6 months [11,13].
A proportion of 46% of the patients completing the
intervention in the probiotic group were compliant
during the whole treatment period (6 months). This is
lower than in former studies. One reason could be
that the patients were to consume four capsules daily,
which is more than in other studies. Furthermore, the
patients were younger than in other studies
[12,13,15,16], most of the patients had no comor-
bidity and were not used to taking medication daily.
The missing effect could partly be explained by the
low compliance, on the other hand the non compli-
ance could also be explained by lacking effect. Of the
non-compliant patients 18 (62%) actually consumed
probiotic in sufﬁcient quantities during 50% of the
treatment months. The level of compliance was con-
ﬁrmed by the fecal analyses, where the probiotic
strains could be detected in 79% of the samples in
the active group.
Simrén et al. [15] and Sondergaard et al. [16] used
the same probiotic mixture as in this study, but in
fermented milk. Neither was able to detect an effect of
the probiotic. Simrén used the same responder def-
inition and found after 8 weeks of treatment a numer-
ically higher proportion of responders in the probiotic
group. He observed the greatest improvement in the
ﬁrst 4 weeks in contrast to this study. The effect was
sustained in the study of Simrén, but with no differ-
ence between the probiotic group and the placebo
group at the end of the study. It is debatable whether
effect after 1 month is clinically relevant in a group of
patients with a chronic disorder. During the 6-month
treatment, we found the same proportion of respon-
ders and difference between the groups as observed by
Simrén after 8 weeks. We included more patients in
our trial, but the observed difference (11%) was not
within the range of statistical difference (impute
signiﬁcant). The power calculation was based on
ﬁnding a difference of 30% between the groups. It
could be argued that this was rather optimistic in this
population, given the observed effect sizes in meta-
analyses [5,9,10]. We ﬁnd it questionable, however,
whether the difference of 11% is clinically relevant. In
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Figure 2. Proportion of patients reporting adequate relief of symptoms during treatment and follow-up. ITT- analysis, probiotic group
(n = 67), placebo.
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a population suffering from a benign disorder, one
could, however, argue that even a slight reduction of
symptoms in a minor group of patients is worthwhile
as long as the therapy is safe. No serious adverse
effects have been reported in IBS-trials on probiotics
[5,9,10], which was also the case in our study. On the
other hand there is a risk of keeping a large part of the
patients in the belief that they need medicine even
though there might be no clinical efﬁcacy [27].
Until now only three long-term studies have been
conducted [11–13]. The Finnish trials used a probi-
otic mixture (Lactobacillus rhamnosusGG, L.rhamnosus
LC705, Biﬁdobacteriuum breve Bb99/B.animalis spp.
lactis Bb12 and propionibacterium freudenreichii spp.
Shermanii JS) and concluded that the probiotic mix-
ture was effective in alleviating IBS symptoms after
5 and 6 months of treatment, respectively. In an
Israeli trial, using capsules containing L. reuteri, no
effect was proven. Proofs of efﬁcacy were in all studies
based on change in composite symptom scores, but
whether the change was clinically relevant to the
patients was only brieﬂy discussed, and only in the
5-month trial was concurrent improvement in quality
of life observed [12]. In the present study we found a
greater improvement in some of the GI symptoms
after three months in the placebo group, but after
6 months no difference between the groups was
observed. This supports the ﬁnding of no signiﬁcant
difference in the primary outcome. The observations
should, however, be interpreted with caution because
of the possibility of multiplicity.
IBS patients are known to have impaired health-
related quality of life [28]. In this study patients
improved in HrQOL during the intervention and
follow-up, probably due to a Hawthorn effect since
no difference between the groups was observed.
To conclude, in this primary care population we
were not able to detect a positive effect of a 6-month
treatment with probiotics when compared with
placebo.
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